AstraZeneca Urges Re-Examination of Unintended Consequences of Inflation Reduction Act on American Cancer and Rare Disease Patients
August 26, 2023
August 26, 2023
WILMINGTON, Delaware, Aug. 26 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Aug. 25, 2023:
To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA). The drug price negotiation provisions of the IRA run headlong into the goals of the Orphan Drug Act (ODA), a federal statute designe . . .
To help protect access to medicines for cancer and rare disease patients, AstraZeneca today has filed a legal challenge to critical aspects of the drug price negotiation provisions of the Inflation Reduction Act (IRA). The drug price negotiation provisions of the IRA run headlong into the goals of the Orphan Drug Act (ODA), a federal statute designe . . .